Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:LNTH NYSE:NUVB NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$33.62+2.3%$29.25$14.32▼$36.28$6.75B0.762.52 million shs1.14 million shsLNTHLantheus$104.52+0.2%$90.68$47.25▼$104.57$6.79B-0.031.01 million shs687,403 shsNUVBNuvation Bio$4.91+3.0%$4.73$1.57▼$9.75$1.66B1.524.41 million shs5.25 million shsSYRESpyre Therapeutics$80.79+0.0%$69.53$13.93▼$84.43$7.01B3.051.01 million shs958,641 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+5.45%+0.64%+14.76%+34.70%+103.59%LNTHLantheus+4.07%+1.46%+8.41%+31.24%+29.19%NUVBNuvation Bio+3.47%-7.73%-1.44%+7.64%+117.05%SYRESpyre Therapeutics+7.58%+2.92%+7.64%+102.48%+348.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$33.62+2.3%$29.25$14.32▼$36.28$6.75B0.762.52 million shs1.14 million shsLNTHLantheus$104.52+0.2%$90.68$47.25▼$104.57$6.79B-0.031.01 million shs687,403 shsNUVBNuvation Bio$4.91+3.0%$4.73$1.57▼$9.75$1.66B1.524.41 million shs5.25 million shsSYRESpyre Therapeutics$80.79+0.0%$69.53$13.93▼$84.43$7.01B3.051.01 million shs958,641 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+5.45%+0.64%+14.76%+34.70%+103.59%LNTHLantheus+4.07%+1.46%+8.41%+31.24%+29.19%NUVBNuvation Bio+3.47%-7.73%-1.44%+7.64%+117.05%SYRESpyre Therapeutics+7.58%+2.92%+7.64%+102.48%+348.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3311.05% UpsideLNTHLantheus 2.73Moderate Buy$101.86-2.55% DownsideNUVBNuvation Bio 2.55Moderate Buy$12.50154.84% UpsideSYRESpyre Therapeutics 3.00Buy$91.3313.05% UpsideCurrent Analyst Ratings BreakdownLatest NUVB, LNTH, SYRE, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/4/2026SYRESpyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ALNTHLantheus$1.54B4.41$6.40 per share16.34$16.43 per share6.36NUVBNuvation Bio$62.90M27.15N/AN/A$0.88 per share5.57SYRESpyre Therapeutics$890K7,882.93N/AN/A$7.21 per share11.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1525.1919.36N/A18.05%29.32%15.00%8/5/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest NUVB, LNTH, SYRE, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09LNTHLantheus0.472.832.64NUVBNuvation Bio0.157.447.24SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%LNTHLantheus99.06%NUVBNuvation Bio61.67%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%LNTHLantheus1.70%NUVBNuvation Bio30.11%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableNUVB, LNTH, SYRE, and IMVT HeadlinesRecent News About These CompaniesHealthcare ETFs: From Broad Exposure to Big BreakthroughsJune 11 at 7:14 AM | etftrends.comECapital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYREJune 9 at 3:25 AM | marketbeat.comSpyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from AnalystsJune 7, 2026 | americanbankingnews.comSpyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside PotentialJune 5, 2026 | finance.yahoo.comSpyre Therapeutics Announces Grants of Inducement AwardsJune 5, 2026 | globenewswire.comArrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYREJune 5, 2026 | marketbeat.comSYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock UpJune 4, 2026 | zacks.comScott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 4, 2026 | insidertrades.comSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAJune 3, 2026 | globenewswire.comWhy Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License TermsJune 3, 2026 | finance.yahoo.comSeven Grand Managers LLC Buys Shares of 100,000 Spyre Therapeutics, Inc. $SYREMay 28, 2026 | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 26, 2026 | globenewswire.comPSP Research LLC Takes Position in Spyre Therapeutics, Inc. $SYREMay 20, 2026 | marketbeat.comLifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)May 18, 2026 | theglobeandmail.comSpyre Therapeutics (NASDAQ:SYRE) Director Sells $5,952,000.00 in StockMay 9, 2026 | insidertrades.comSpyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for StockholdersMay 6, 2026 | tipranks.comSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in StockMay 2, 2026 | insidertrades.comSpyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseMay 1, 2026 | finance.yahoo.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVB, LNTH, SYRE, and IMVT Company DescriptionsImmunovant NASDAQ:IMVT$33.62 +0.74 (+2.25%) Closing price 04:00 PM EasternExtended Trading$33.67 +0.05 (+0.16%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Lantheus NASDAQ:LNTH$104.52 +0.20 (+0.19%) Closing price 04:00 PM EasternExtended Trading$104.52 0.00 (0.00%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Nuvation Bio NYSE:NUVB$4.90 +0.15 (+3.05%) Closing price 03:59 PM EasternExtended Trading$5.00 +0.10 (+1.96%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Spyre Therapeutics NASDAQ:SYRE$80.79 +0.02 (+0.02%) Closing price 04:00 PM EasternExtended Trading$81.18 +0.38 (+0.48%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
